You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Bulk Pharmaceutical API Sources for vilazodone hydrochloride


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for vilazodone hydrochloride

Vendor Vendor Homepage Vendor Sku API Url
MedChemexpress MCE ⤷  Start Trial HY-14261 ⤷  Start Trial
AbaChemScene ⤷  Start Trial CS-0549 ⤷  Start Trial
Molport ⤷  Start Trial MolPort-028-744-909 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Vilazodone Hydrochloride

Last updated: February 19, 2026

Vilazodone hydrochloride, marketed as Viibryd, is a serotonin partial agonist and reuptake inhibitor (SPARI) used for depression treatment. The global sourcing landscape for bulk vilazodone API involves a mix of established chemical manufacturers, emerging API producers, and contract manufacturing organizations (CMOs). Quality, regulatory compliance, manufacturing capacity, and cost influence supplier selection.

Key API Manufacturers and Suppliers

Supplier Location Certification & Compliance Capacity Notes
Thermo Fisher Scientific United States FDA, cGMP, ISO 9001 High Offers comprehensive API production, including complex APIs like vilazodone.
Zhejiang Huahai Pharmaceutical China SFDA, cGMP, ISO 9001 Moderate to High Large scale API manufacturing with international distribution.
Shanghai Pharma China NMPA, cGMP, ISO 9001 Moderate Supplies API to various markets, actively expanding capacity.
Jiangsu Hengrui Medicine China CFDA, cGMP, ISO 9001 Moderate Focuses on CNS-active APIs, including vilazodone.
Xincheng Biotechnology China CFDA, cGMP, ISO 9001 Small to Moderate Specializes in niche APIs and intermediates.
Dr. Reddy’s Laboratories India DCGI, cGMP, ISO 9001 Moderate Provides API to North American and European markets.

Contract Manufacturing Organizations (CMOs)

CMO Location Capabilities Regulatory Status Notes
Ajinomoto Bio-PharmaServices United States / Japan Custom API synthesis, scale-up FDA, EMA, ICH Known for complex APIs, high quality standards.
Keppe Pharma Germany API manufacturing, scale-up EMA, ICH, ISO 9001 Focuses on CNS APIs, including vilazodone.
Zhejiang Huahai Pharma China API production, scale-up SFDA, cGMP Large-scale OEM API producer.
Abcam Biosciences India Custom synthesis, supply chain management DCGI, cGMP Offers flexibility in batch size and synthesis routes.

Key Considerations in API Sourcing

  • Regulatory Compliance: Suppliers must meet cGMP standards, with documentation for validation, stability, and purity.
  • Quality Control: Specification adherence for impurity profiles, residual solvents, and potency.
  • Capacity & Lead Time: Sufficient manufacturing capacity to meet demand fluctuations.
  • Pricing: Competitive rates balanced against quality and compliance.
  • Geographical Factors: North American and European markets prefer suppliers with local or compliant manufacturing facilities for faster registration and reduced supply chain risks.

Supply Chain Dynamics

The majority of vilazodone hydrochloride APIs originate from China and India due to manufacturing scale and cost advantage. Global regulations and trade policies have increased scrutiny on API imports, influencing due diligence and qualification processes. Major branded and generic pharmaceutical companies source from a mix of CMOs and in-house manufacturing, with some relying on multiple suppliers to mitigate risk.

Recent Developments & Market Trends

  • Increased Regulatory Oversight: US FDA and EMA have tightened inspections of Chinese and Indian API facilities, affecting supply stability.
  • Supply Chain Diversification: Companies are diversifying sources to avoid disruptions caused by geopolitical or quality issues.
  • Capacity Expansion: Several API manufacturers have announced capacity expansions in China and India to meet rising demand for CNS APIs like vilazodone.
  • Generic Competition: Availability of generic vilazodone is driven by multiple manufacturers, intensifying price competition.

Key Takeaways

  • Most bulk vilazodone hydrochloride APIs are produced in China and India, with increasing capacity from domestic manufacturers.
  • Suppliers must meet strict cGMP standards for global pharmaceutical markets.
  • Contract manufacturing organizations provide scalable, compliant synthesis options, often with quicker lead times.
  • Regulatory scrutiny on Asian API sources has increased, leading to potential supply chain adjustments.
  • Companies sourcing vilazodone APIs should evaluate capacity, compliance, and geopolitical considerations during supplier qualification.

Frequently Asked Questions

1. Are there US-based suppliers for vilazodone hydrochloride API?
US-based suppliers are rare; most APIs are sourced from Chinese and Indian manufacturers, with some North American CMOs offering custom synthesis under strict regulatory standards.

2. What are the main quality criteria for vilazodone API?
Purity (>98%), impurity profile compliance, residual solvents within ICH limits, and batch-to-batch consistency.

3. How does API pricing influence supplier choice?
Lower-cost APIs from China and India dominate due to scale; however, quality and supply reliability are critical, often outweighing initial cost savings.

4. Can alternative synthesis routes impact supply security?
Yes, alternative synthesis routes or intermediates can mitigate risks associated with specific manufacturing sites or chemical processes.

5. What regulatory hurdles exist in sourcing vilazodone API internationally?
Manufacturers must demonstrate compliance with cGMP, provide validation data, and ensure traceability to meet US FDA, EMA, and other authorities' standards.


References

[1] U.S. Food and Drug Administration. (2023). Guidance for Industry: Chemical Facility Anti-Terrorism Standards (CFATS).
[2] International Conference on Harmonisation. (2022). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[3] European Medicines Agency. (2023). Guidelines on the quality of active substances.
[4] PMC. (2021). Market analysis of API manufacturing in India and China.
[5] Pharmaceutical Technology. (2022). Global API supply chain restructuring.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.